Table 1.
Sex: F/M | 70/30 |
---|---|
Age, years: mean ± SD | 37.3 ± 10.6 |
Disease duration, months: mean ± SD | 30.5 ± 46.6 |
Disease severity, EDSS: mean ± SD | 2.0 ± 1.3 |
CA MS: n/total (%) | 77/100 (77%) |
CS MS: n/total (%) | 23/100 (23%) |
Gd+ MS: n/total (%) | 37/100 (37%) |
Gd- MS: n/total (%) | 63/100 (63%) |
Blood-CSF-barrier dysfunction, QAlb: positive/total (%) | 18/100 (18%) |
Intrathecal IgG synthesis, IgG Index: positive/total (%) | 71/100 (71%) |
CSF-restricted oligoclonal IgG bands: positive/total (%) | 84/100 (84%) |
CA, clinically active (presence of relapse at entry); CS, clinically stable (absence of relapse at entry); EDSS, expanded disability status scale; Gd+, appearance of gadolium enhancing lesions on magnetic resonance imaging (MRI); Gd-, no evidence of gadolium enhancing on MRI; QAlb, CSF/serum albumin quotient.